drugset / Trial / NCT00148395

Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.

NCT00148395

Phase 3 Completed 280 enrolled Aktion Bronchialkarzinom e.V.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study wants to assess different intensive therapy sequences for the treatment of non-small-cell lung cancer. It claims less on the efficacy of different chemotherapy combinations, than more on the comparison of different strategies of sequential single-agent, sequential double-agent or sequential triple-agent therapy.

Timeline

Start
2002-06
Primary completion
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule
Subject Cisplatin Other / unclassified
Subject Gemcitabine Small molecule
Subject Ifosfamide Small molecule
Subject Mitomycin C Other / unclassified
Subject Vinorelbine Small molecule